Joth Jacobson

3.1k total citations
34 papers, 2.3k citations indexed

About

Joth Jacobson is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Joth Jacobson has authored 34 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hematology, 12 papers in Oncology and 10 papers in Molecular Biology. Recurrent topics in Joth Jacobson's work include Multiple Myeloma Research and Treatments (16 papers), Cancer Treatment and Pharmacology (7 papers) and Protein Degradation and Inhibitors (4 papers). Joth Jacobson is often cited by papers focused on Multiple Myeloma Research and Treatments (16 papers), Cancer Treatment and Pharmacology (7 papers) and Protein Degradation and Inhibitors (4 papers). Joth Jacobson collaborates with scholars based in United States, Austria and Denmark. Joth Jacobson's co-authors include Bart Barlogie, Guido Tricot, John Crowley, Maurizio Zangari, Elias Anaissie, Athanasios Fassas, John D. Shaughnessy, Sundar Jagannath, David H. Vesole and Brian G.M. Durie and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Clinical Oncology and Blood.

In The Last Decade

Joth Jacobson

34 papers receiving 2.3k citations

Peers

Joth Jacobson
Donna Weber United States
Marinus van Marwijk Kooy Netherlands
Edward N. Libby United States
Susanna Jacobus United States
Rachid Baz United States
Elliott F. Winton United States
David Irwin United States
Raman Desikan United States
Jae Hoon Lee South Korea
Leonard T. Heffner United States
Donna Weber United States
Joth Jacobson
Citations per year, relative to Joth Jacobson Joth Jacobson (= 1×) peers Donna Weber

Countries citing papers authored by Joth Jacobson

Since Specialization
Citations

This map shows the geographic impact of Joth Jacobson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joth Jacobson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joth Jacobson more than expected).

Fields of papers citing papers by Joth Jacobson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joth Jacobson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joth Jacobson. The network helps show where Joth Jacobson may publish in the future.

Co-authorship network of co-authors of Joth Jacobson

This figure shows the co-authorship network connecting the top 25 collaborators of Joth Jacobson. A scholar is included among the top collaborators of Joth Jacobson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joth Jacobson. Joth Jacobson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Fagan, Thomas E., et al.. (2008). Fracture of the GORE HELEX septal occluder: Associated factors and clinical outcomes. Catheterization and Cardiovascular Interventions. 73(7). 941–948. 27 indexed citations
3.
Jones, Thomas K., Larry Latson, Evan M. Zahn, et al.. (2007). Results of the U.S. Multicenter Pivotal Study of the HELEX Septal Occluder for Percutaneous Closure of Secundum Atrial Septal Defects. Journal of the American College of Cardiology. 49(22). 2215–2221. 124 indexed citations
4.
Latson, Larry, Thomas K. Jones, Joth Jacobson, Evan M. Zahn, & John F. Rhodes. (2006). Analysis of factors related to successful transcatheter closure of secundum atrial septal defects using the HELEX septal occluder. American Heart Journal. 151(5). 1129.e7–1129.e11. 34 indexed citations
5.
Zangari, Maurizio, Bart Barlogie, Elias Anaissie, et al.. (2004). Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. British Journal of Haematology. 126(5). 715–721. 168 indexed citations
6.
Anaissie, E., Joth Jacobson, Athanasios Fassas, et al.. (2003). Safety of total therapy II with or without thalidomide (THAL) for newly diagnosed myeloma: A study of 475 consecutive patients. Blood. 102(11). 1 indexed citations
7.
Dhodapkar, Madhav V., Joth Jacobson, Morie A. Gertz, John J. Crowley, & Bart Barlogie. (2003). Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: An update of a US intergroup trial (SW0G S9003). Seminars in Oncology. 30(2). 220–225. 50 indexed citations
8.
Jacobson, Joth, Bart Barlogie, John D. Shaughnessy, et al.. (2003). MDS‐type abnormalities within myeloma signature karyotype (MM‐MDS): only 13% 1‐year survival despite tandem transplants. British Journal of Haematology. 122(3). 430–440. 28 indexed citations
9.
Zangari, Maurizio, Bart Barlogie, Raymond Thertulien, et al.. (2003). Thalidomide and Deep Vein Thrombosis in Multiple Myeloma: Risk Factors and Effect on Survival. Clinical Lymphoma. 4(1). 32–35. 86 indexed citations
10.
Jacobson, Joth, Mohamad A. Hussein, Bart Barlogie, Brian G.M. Durie, & John J. Crowley. (2003). A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. British Journal of Haematology. 122(3). 441–450. 88 indexed citations
11.
Badros, Ashraf, Bart Barlogie, Christopher Morris, et al.. (2003). Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Experimental Hematology. 31(1). 73–80. 71 indexed citations
12.
Shaughnessy, John D., Erming Tian, Jeffrey R. Sawyer, et al.. (2002). Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization‐defined chromosome 13 deletion in multiple myeloma: early results of total therapy II. British Journal of Haematology. 120(1). 44–52. 115 indexed citations
13.
LeBlanc, Michael, Joth Jacobson, & John Crowley. (2002). Partitioning and peeling for constructing prognostic groups. Statistical Methods in Medical Research. 11(3). 247–274. 23 indexed citations
14.
Presant, Cary A., Joth Jacobson, Walter Wolf, et al.. (2002). Does Leucovorin Alter the Intratumoral Pharmacokinetics of 5-Fluorouracil (5-FU)? A Southwest Oncology Group Study. Investigational New Drugs. 20(4). 369–376. 16 indexed citations
15.
Crowley, John, Joth Jacobson, & R. Alexanian. (2001). Standard-dose therapy for multiple myeloma: The Southwest Oncology Group experience. Seminars in Hematology. 38(3). 203–208. 12 indexed citations
16.
Macdonald, John S., Joth Jacobson, Manuel Modiano, et al.. (2000). A Phase II Trial of Etoposide, Leucovorin, 5-FU, and Interferon Alpha 2b (ELFI) + G-CSF for Patients with Pancreatic Adenocarcinoma: a Southwest Oncology Group Study (SWOG 9413). Investigational New Drugs. 18(3). 269–273. 15 indexed citations
17.
Holcombe, Randall F., Joth Jacobson, Shaker R. Dakhil, et al.. (1999). Association of immune parameters with clinical outcome in stage III colon cancer: results of Southwest Oncology Group Protocol 9009. Cancer Immunology Immunotherapy. 48(9). 533–539. 16 indexed citations
18.
Holcombe, Randall F., Joth Jacobson, Ailing Li, & Carol M. Moinpour. (1999). Inclusion of Black Americans in Oncology Clinical Trials. American Journal of Clinical Oncology. 22(1). 18–21. 37 indexed citations
19.
Meyskens, Frank L., Joth Jacobson, Bichlien Nguyen, et al.. (1998). Phase II trial of oral β-all trans-retinoic acid in hepatocellular carcinoma (SWOG 9157). Investigational New Drugs. 16(2). 171–173. 20 indexed citations
20.
Hess, L. D., Joth Jacobson, Kurt Schaffner, & James N. Pitts. (1967). Structure and reactivity in the vapor-phase photolysis of ketones. V. Aliphatic cyclopropyl and olefinic ketones. Journal of the American Chemical Society. 89(15). 3684–3688. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Donna Weber Breakdown of academic impact, for papers by Marinus van Marwijk Kooy Breakdown of academic impact, for papers by Edward N. Libby Breakdown of academic impact, for papers by Susanna Jacobus Breakdown of academic impact, for papers by Rachid Baz Breakdown of academic impact, for papers by Elliott F. Winton Breakdown of academic impact, for papers by David Irwin Breakdown of academic impact, for papers by Raman Desikan Breakdown of academic impact, for papers by Jae Hoon Lee Breakdown of academic impact, for papers by Leonard T. Heffner
Rankless by CCL
2026